ArticleScientific reports2025
Synthesis, characterization, and comparative evaluation of hydroxychloroquine and its niosomal nanoformulation: anti-leishmanial, cytotoxicity, and immunomodulatory effects in photodynamic therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- NanoformulatedNanomaterials (Basel, Switzerland) · 2026Article
- Immune Efficacy of a Vaccine Candidate Based on Binding Protein 26 (BP26) from Brucella melitensis Encapsulated in Niosome Nanoparticles Against Brucellosis.Pharmaceutical research · 2026Article
- Enhanced Topical Treatment of Cutaneous Leishmaniasis Using Niosomal Gel of Tioxolone-Benzoxonium Chloride: In silico, in vitro, and in vivo Evaluation.Research and reports in tropical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Leishmaniasis, caused by the Leishmania parasites, is a significant global health issue with treatment challenges, particularly in endemic regions such as Iran. Current therapies, such as Meglumine antimoniate (MA), Amphotericin B, and Miltefosine, have limitations like high costs and side effects, necessitating innovative approaches. This study evaluates hydroxychloroquine (HC), an antimalarial drug with immunomodulatory properties, against Leishmania tropica (L. tropica), the causative agent of cutaneous leishmaniasis. We explored photodynamic therapy (PDT) and encapsulated HC in niosomal delivery systems with CdS/MIL-125(Ti) nanocomposites (FN) to enhance drug targeting. PDT utilizes these materials to produce reactive oxygen species, targeting cells effectively. Hydroxychloroquine-CdS/MIL-125(Ti)-loaded niosomes (NHC) were synthesized, characterized, and their in vitro anti-leishmanial activities were assessed alongside HC and MA. Results showed that NHC significantly improved anti-leishmanial effects, reducing viability in both promastigote and amastigote forms. Additionally, HC demonstrated favorable interactions with key proteins through molecular docking, modulated cytokine production, and induced apoptosis in infected macrophages. PDT further boosted the efficacy of both HC and NHC. This study indicates that niosomal encapsulation of HC enhances its delivery and efficacy, highlighting the potential for combination therapies in treating L. tropica. Further, in vivo studies are recommended to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.